Navigation Links
Trial seeks 'genetic fingerprint' for predicting drug effectiveness

CINCINNATIUniversity of Cincinnati (UC) physician-scientists believe identifying a genetic fingerprint could help predict which specific therapies will be most effective for patients with gastric cancer.

Syed Ahmad, MD, is leading a national, phase-2 trial to test the effectiveness of combined chemotherapy and radiation therapy given to patients with gastric cancer before surgery. His team will also collect biological samples in an attempt to obtain genetic data that could be used to formulate targeted therapies.

Previous studies have established that either chemotherapy or radiation therapy after surgery can improve patient survival compared with surgery alone. Overall survival rates, however, remain lowwith 20 to 30 percent of American patients surviving more than five years after treatment.

Everyone agrees that without surgery, gastric cancer in not curable, and numerous studies have shown a benefit to follow-up therapy with either chemotherapy or radiation therapy, says Ahmad, assistant professor of surgery at UC and principal investigator of the trial.

The problem is you cant give both radiation therapy and chemotherapy after surgeryits too toxic and patients cant tolerate it, he says. But you can give it before surgery when patients are healthiest.

This trial addresses what Ahmad calls the future of cancer therapy: targeted drug regimens, based on the characteristics of a patients specific tumor.

His goal is to identify a genetic fingerprint that could help predict whether patients will respond to therapy, and then identify drugs to address the specific molecular characteristics of that patients tumor.

Right now treatment is based on the assumption that site-based cancers are all the same, so every patient who has stage-3 gastric cancer will get the same chemotherapy drugs, Ahmad explains. But the reality is that every cancer has a different expression of hormones, growth factors and genetic factors that must be addressed individually.

The UC-led national team is looking for about 70 patients across the United States with up to stage-3 gastric cancer to participate in the trial.

Prior to surgery, all study participants will have a biopsy to set baseline standards for genetic testing to determine which patients have a complete response to the multi-treatment therapy. Participants will receive daily doses of the platinum-containing drug oxaliplatin (ox-AL-ih-plah-tin, marketed as Eloxatin) for six to eight weeks.

Approved by the Food and Drug Administration, oxaliplatin is currently used to treat advanced colorectal cancer. Studies have shown the drug has fewer toxicity complications compared with other therapies.

After six weeks of chemotherapy, the patient will get five consecutive days of three-dimensional, external-beam radiation therapy. Patients will be reevaluated two to three weeks after radiation to determine if they are eligible for surgery. Those who are suitable will have another tissue biopsy after surgery.

Researchers will compare pre- and post-surgery tissue samples to obtain the genetic data necessary to establish associations between molecular markers and drug resistance, with the goal of reducing toxicity associated with chemotherapeutic agents and improving patient survival.


Contact: Amanda Harper
University of Cincinnati

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. NIAID Initiates Trial of Experimental Avian Flu Vaccine
3. International trial of two microbicides begins
4. Bird Brains Show How Trial and Error May Contribute to Learning
5. Use of PET can reduce, may eliminate more strenuous drug development trials with animals
6. HIV vaccine trial breaks ground for future research
7. Roche clinical trial registry and results database launched
8. NIAID begins clinical trial of West Nile virus vaccine
9. EuroVacc 02 HIV Vaccine Trial Begins
10. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
11. Compound might defeat African sleeping sickness, clinical trial beginning this month
Post Your Comments:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... maternal age to IVF success. , After comparing the results from the fresh ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Rotary Club. The event entitled “Stem Cells and Their Regenerative Powers,” ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology: